This indicates that downstream effects associated with RBM20-DCM such as changing the gene expression profile of non-cardiomyocytes were repaired even though the AAVMYO-ABE treatment specifically targets cardiomyocytes. This evidence concerns the gene RBM20 and familial dilated cardiomyopathy.